Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Telesta Therapeutics Inc.

Division of Prometic Life Sciences Inc.
www.telestatherapeutics.com

Latest From Telesta Therapeutics Inc.

Deal Watch: Ferring Enters New Therapeutic Area With Phase III Sciatica Candidate

Trek Therapeutics expands its HCV pipeline by in-licensing polymerase inhibitor from Medivir. ProMetic gains cash, tax offsets and physical plant by acquiring fellow Canadian firm Telesta for pennies per share, while Cell Medica inks its second academic cancer immunotherapy collaboration of 2016, this time with University College London.

Deals M & A

FDA New Drug Approval Count May Fall Back To Earth In 2016

A repeat of FDA’s record-breaking NME approval performance from recent years looks unlikely, even though the 14 novel approvals in the first half of 2016 equals the first half total for 2015, because almost one-third fewer novel candidates have user fee goals in the second half.

Regulation BioPharmaceutical

Heat Biologics Tightens Belt To Reach Late-2016 Inflection Points

Biotech striving to hold on financially until it can deliver top-line data for bladder and lung cancer immunotherapy candidates, but then it will have to content with Roche entering the bladder cancer market with its PD-L1 inhibitor.

BioPharmaceutical United States

Keeping Track: FDA Turns Down Telesta's MCNA, Broader Use Of Vertex' Kalydeco

The latest drug development news and highlights from our FDA Performance Tracker.

BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Bioniche Life Sciences Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Prometic Life Sciences Inc.
  • Senior Management
  • Michael Berendt, PhD, CEO & Chief Scientist
    Brian Ford, CFO
    Monique Champagne, VP, Clin. Research
    Donald Olds, COO
    Brian Groch, CCO
    Mathieu Boudreau, PhD, VP, Corp Dev and Licensing
  • Contact Info
  • Telesta Therapeutics Inc.
    Phone: (514) 697-6636
    2600 Alfred-Nobel
    Suite 301
    Saint-Laurent, H4S 0A9
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register